Simvastatin in New Zealand
This article was originally published in The Tan Sheet
Executive Summary
The Medicines Classifications Committee of New Zealand's Ministry of Health unanimously denies HeartCare Plus' application for pharmacy-only sale of simvastatin, according to minutes from a meeting on the reclassification recently made available. Committee members were "not convinced" of "the efficacy of a 10 mg tablet" and said reliable blood tests, blood pressure and physical exams "could not be undertaken at pharmacy-only level." The minutes also announce the committee's approval of pharmacy-only sale of Aventis' Nasacort for allergenic rhinitis. However, the committee deferred its recommendation on classification for Roche's Xenical until it obtains assurance that "pharmacists would be trained to sell the product according to the adopted protocol. The committee convened in May to discuss the switches (1"The Tan Sheet" May 31, 2004, p. 6)...
You may also be interested in...
Simvastatin, Xenical, Nasacort Switch Decisions Imminent In New Zealand
New Zealand's Ministry of Health is expected to issue a decision on behind-the-counter switches for simvastatin, Roche's Xenical and Aventis' Nasacort within four to six weeks
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.